TLR4 Antagonist Patent for Multiple Myeloma Treatment EP3558323A1
Summary
The European Patent Office granted patent EP3558323A1 for specific TLR4 antagonists in the treatment of multiple myeloma. The patent applicants include Etablissement Français du Sang, CNRS, Université Paul Sabatier Toulouse III, and INSERM. Designated states cover all EU member states plus other EPC contracting states.
What changed
The EPO published patent application EP3558323A1 claiming specific TLR4 antagonists for treating multiple myeloma. The invention covers pharmaceutical compositions comprising TLR4 antagonists and methods of treatment using those compositions.\n\nPharmaceutical companies and researchers in cancer therapeutics should monitor this patent for potential licensing needs or freedom-to-operate considerations. The designated states include all EU member states, making this patent enforceable across the European market.
What to do next
- Monitor EPO register for patent status updates
- Review patent claims for licensing opportunities
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA
Publication EP3558323A1 Kind: A1 Apr 08, 2026
Applicants
Etablissement Français du Sang, Centre National de la Recherche Scientifique, Université Paul Sabatier Toulouse III, Institut National de la Santé et de la Recherche
Médicale
Inventors
ESPAGNOLLE, Nicolas, DESCHASEAUX, Frédéric, SENSEBE, Luc, BOURIN, Philippe
IPC Classifications
A61K 31/7008 20060101AFI20180629BHEP A61P 35/00 20060101ALI20180629BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.